<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182037</url>
  </required_header>
  <id_info>
    <org_study_id>1193.1</org_study_id>
    <nct_id>NCT02182037</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacodynamics, and Pharmacokinetics of BIBT 1011 BS in Healthy Subjects</brief_title>
  <official_title>Safety, Pharmacodynamics, and Pharmacokinetics After Single Oral Administration of 1, 5, 10, 30, 100, 200 and 400 mg BIBT 1011 BS as Drinking Solution in Healthy Subjects. An Open, Placebo-controlled, Randomised Study, Double Blind at Each Dose Level</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      A study to assess safety, pharmacokinetics and the effect of BIBT 986 BS, given as BIBT 1011&#xD;
      BS, on coagulation parameters.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <primary_completion_date type="Actual">September 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of activated partial thromboplastin time (aPTT)</measure>
    <time_frame>Pre-dose, up to 48 hours after start of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of international normalized ration (INR)</measure>
    <time_frame>Pre-dose, up to 48 hours after start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of thrombin time (TT)</measure>
    <time_frame>Pre-dose, up to 48 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of ecarin clotting time (ECT)</measure>
    <time_frame>Pre-dose, up to 48 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of plasma concentration time profiles of BIBT 986 BS</measure>
    <time_frame>Pre-dose, up to 48 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of BIBT 986 BS in plasma (Cmax)</measure>
    <time_frame>Pre-dose, up to 48 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve for BIBT 986 BS (AUC)</measure>
    <time_frame>Pre-dose, up to 48 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to when the plasma concentration reaches Cmax after a single extravascular dose (tmax)</measure>
    <time_frame>Pre-dose, up to 48 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total mean time of residence of BIBT 986 BS- molecules in the body (MRTtot)</measure>
    <time_frame>Pre-dose, up to 48 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution of the analytes during the terminal phase (Vz/f)</measure>
    <time_frame>Pre-dose, up to 48 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half life of BIBT 986 BS in plasma (t1/2)</measure>
    <time_frame>Pre-dose, up to 48 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount excreted over the 24 hour sampling period (Ae0-24)</measure>
    <time_frame>Pre-dose, up to 24 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total clearance after oral administration (CLtot/F)</measure>
    <time_frame>Pre-dose, up to 48 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to 17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of BIBT 986 BS plasma concentration- aPTT relationship</measure>
    <time_frame>Pre-dose, up to 48 hours after start of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BIBT 1011 BS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBT 1011 BS placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single rising doses of BIBT 1011 BS</intervention_name>
    <arm_group_label>BIBT 1011 BS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBT 1011 BS placebo</intervention_name>
    <arm_group_label>BIBT 1011 BS placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subjects as determined by results of screening&#xD;
&#xD;
          -  Signed written informed consent in accordance with good clinical practice (GCP) and&#xD;
             local legislation&#xD;
&#xD;
          -  Age ≥ 18 and ≤ 45 years&#xD;
&#xD;
          -  Body Mass Index ≥ 18.5 and ≤ 29.9 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any finding of the medical examination (including blood pressure, pulse rate and ECG)&#xD;
             deviating from normal and of clinical relevance&#xD;
&#xD;
          -  History or current gastrointestinal, hepatic, renal, respiratory, cardiovascular,&#xD;
             metabolic, immunological, hormonal disorders&#xD;
&#xD;
          -  History of orthostatic hypotension, fainting spells or blackouts&#xD;
&#xD;
          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders&#xD;
&#xD;
          -  Chronic or relevant acute infections&#xD;
&#xD;
          -  History of&#xD;
&#xD;
               -  allergy/hypersensitivity (including drug allergy) which is deemed relevant to the&#xD;
                  trial as judged by the investigator&#xD;
&#xD;
               -  any bleeding disorder including prolonged or habitual bleeding&#xD;
&#xD;
               -  other hematologic disease&#xD;
&#xD;
               -  cerebral bleeding (e.g. after a car accident)&#xD;
&#xD;
               -  commotio cerebri&#xD;
&#xD;
          -  Intake of drugs with a long half-life (&gt; 24 hours) within 1 month prior to&#xD;
             administration&#xD;
&#xD;
          -  Use of any drugs which might influence the results of the trial within 10 days prior&#xD;
             to administration or during the trial&#xD;
&#xD;
          -  Participation in another trial with an investigational drug within 2 months prior to&#xD;
             administration or during trial&#xD;
&#xD;
          -  Smoker (&gt;10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from&#xD;
             smoking on study days&#xD;
&#xD;
          -  Alcohol abuse (&gt; 60 g/day)&#xD;
&#xD;
          -  Drug abuse&#xD;
&#xD;
          -  Blood donation within 1 month prior to administration or during the trial&#xD;
&#xD;
          -  Excessive physical activities within 5 days prior to administration or during the&#xD;
             trial&#xD;
&#xD;
          -  Any laboratory value outside the clinically accepted reference range&#xD;
&#xD;
          -  History of any familial bleeding disorder&#xD;
&#xD;
          -  Thrombocytes &lt; 150000/µl&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1193/1193.1_U02-1339.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>July 2, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

